Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML

BIO-PATH HOLDINGS, INC.

Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.
Cohort 2 (relapsed/refractory AML): 55% of evaluable patients (12/23) achieved CR/CRi/CRh; median age 63 yrs.
Safety profile consistent with decitabine+venetoclax; common AEs: fatigue (72%), anemia (60%), neutropenia (49%).
Bio-Path plans to continue enrollment up to 98 evaluable in Cohort 1 and 54 evaluable in Cohort 2.
Data presented as oral presentation at ASCO 2024 by MD Anderson investigator; CEO highlights unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.